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Linezolid-Resistant 
Staphylococcus 
cohnii, Greece
To the Editor: Since 2003, li-
nezolid has typically been used to 
treat infections caused by multidrug-
resistant gram-positive cocci such 
as vancomycin-resistant Enterococ-
cus faecium and methicillin-resistant 
Staphylococcus aureus (1). In Greece, 
a major problem is nosocomial dis-
semination of vancomycin-resistant 
enterococci. Use of linezolid for the 
treatment of such infections led to the 
emergence of linezolid–vancomycin 
resistant E. faecium; however, linezol-
id resistance of staphylococci is still 
relatively low in this country (2). We 
describe an outbreak caused by a line-
zolid-resistant S. cohnii in an intensive 
care unit (ICU) in Greece.
From July through October 2007, 
nonrepetitive coagulase-negative sta-
phylococci that exhibited resistance 
to linezolid, were isolated from blood 
cultures from 4 separate patients hos-
pitalized in the ICU at Sismanoglion 
General Hospital of Athens, a 450-bed 
tertiary care hospital. The ICU is a 10-
bed, level II unit, comprising 2 rooms 
with 1 bed each and 2 rooms with 4 
beds each. Each isolate was recovered 
in 2 of 2 blood culture sets per patient, 
indicating true bacteremia. The demo-
graphic and clinical information for 
the patients is described in the Table. 
The mean duration of time preceding 
linezolid therapy was 22 days.
Isolates were ﬁ  rst  identiﬁ  ed  to 
the species level by using an API 
Staph system (bioMérieux, la Balme 
les Grottes, France) and a molecular 
method based on the tuf gene followed 
by sequencing analysis (3). Suscepti-
bility testing for various antimicrobial 
agents was performed by disk diffu-
sion and using Clinical Laboratory 
Standards Institute criteria; suscep-
tibilities were interpreted according 
to Institute guidelines (4). In addi-
tion, MICs to oxacillin, vancomycin, 
teicoplanin, quinupristin-dalfopristin, 
linezolid, daptomycin, and tigecy-
cline were determined by Etest (AB 
Biodisk, Solna, Sweden) according 
to manufacturer’s instructions. Re-
sistance genes mecA, vat,  vga, erm, 
aac(6´)-Ie+aph(2″),  ant(4′)-Ia, and 
aph(3′)-IIIa, as markers for resistance 
to β-lactams, dalfopristin, macrolides, 
and aminoglycosides, were identiﬁ  ed 
by PCR as previously reported (5,6). 
The presence of G2576T in domain 
V of the 23S rRNA, which is mainly 
associated with linezolid resistance in 
clinical isolates, was detected by us-
ing PCR and digestion of the product 
with NheI (2). The number of mutated 
versus nonmutated alleles was deter-
mined as described by Pillai et al. (7). 
In addition, isolates were examined 
for the presence of the cfr gene, which 
was found to be correlated with lin-
ezolid resistance in some coagulase-
negative staphylococci and for mu-
tations of ribosomal protein L4, L22 
genes (8,9). Clonality of isolates was 
assessed by pulsed-ﬁ  eld gel electro-
phoresis (PFGE) after digestion of 
chromosomal DNA with SmaI (2).
The molecular method identiﬁ  ed 
the isolates as S. cohnii subsp. ure-
olyticus. The API Staph system has 
correctly identiﬁ  ed 2 of them; the re-
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maining 2 isolates were falsely char-
acterized as S. xylosus. According to 
disc diffusion test results, the isolates 
were resistant to cefoxitin, oxacillin, 
penicillin, rifampin, quinupristin-dal-
fopristin, erythromycin, clindamycin, 
fusidic acid, tobramycin, gentamicin, 
and linezolid. MICs were linezolid 32, 
oxacillin 256, quinupristin-dalfopristin 
8, vancomycin 2, teicoplanin 2, tigecy-
cline 0.125, and daptomycin 0.5 mg/L. 
Molecular methods detected the fol-
lowing resistance genes: mecA, ermA, 
aac(6´)-Ie+aph(2″), and aph(3´)-IIIa. 
The isolates, despite their resistance to 
streptogramins, were negative for vat 
and vgaA genes. In addition, all iso-
lates carried the G2576T mutation and 
had 4 of 5 mutated alleles. No isolate 
carried the cfr gene or any mutation on 
ribosomal protein L4 and L22 genes. 
PFGE results indicated that all isolates 
were clonally related, belonging to the 
same clone.
Outbreaks caused by linezolid-
resistant staphylococci are rare world-
wide (10); in Sismanoglion Hospital, 
before the outbreak period, no line-
zolid-resistant staphylococci and en-
terococci had been isolated. However, 
in the ICU, a statistically signiﬁ  cant 
increase in the use of linezolid was 
observed in 2004 and in 2007 (0.58 
vs. 1.34 deﬁ  ned daily doses/100 pa-
tient-days, respectively); heavy use of 
linezolid may have created substan-
tial selection pressure in favor of the 
linezolid-resistant isolates.
The 4 patients were treated in the 
same room by the same personnel; 
thus, a potential explanation for this 
outbreak is patient-to-patient trans-
mission of linezolid-resistant strains 
on the hands of healthcare personnel. 
However, cultures of ICU personnel 
(nasal cavity and hands) grew only 
methicillin-resistant  S. aureus and 
methicilllin-resistant  S. epidermidis. 
In addition, environmental samples 
taken from the beds and the equipment 
of these patients were negative for S. 
cohnii. Strict control measures were 
taken (e.g., isolation of infected pa-
tients, increased environmental clean-
ing, and reinforcement of proper glove 
and gown use and hand disinfection 
with alcohol gel), and the outbreak 
strain was not recovered from other 
patients in the ICU or in other depart-
ments of the hospital after the initial 
outbreak. In conclusion, to avoid 
spread of staphylococcal resistance in 
ICUs, measures such as hand hygiene 
and adequate central venous catheter 
handling should be taken, and policies 
regarding antimicrobial drug use must 
be applied.
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Table. Clinical characteristics of 4 patients from whom linezolid-resistant Staphylococcus cohnii  was isolated, Greece, 2007* 
Patient
no.
Gender/ 
age, y
Medical
history
Reason
for hospitalization
Previous
treatment
Date of 
hospital
admission
Date of 
sample
collection Outcome
Date of 
death or 
discharge
1 F/82 No relevant 
history
Acute cholecystitis, 
necrotizing pancreatitis
CIP, CAZ, IMP, 
TZP, LIN
May 10 Jul 20 Death Aug 21
2 M/38 Alcoholism Lung abscess CIP, CAZ, LIN Jul 14 Aug 21 Recovery  Oct 20
3 M/52 COPD, melitensus 
diabetes
Necrotizing pneumonia TZP, CLI, IMP, 
LIN
Aug 21 Sep 25 Recovery  Oct 30
4 M/65 No relevant 
history
Septic shock IMP, CIP, TZP, 
LIN
Sep 17 Oct 28 Recovery  Dec 10
*CIP, ciprofloxacin; CAZ, ceftazidime; IMP, imipenem; TZP, piperacillin-tazobactam; LIN, linezolid; CLI, clindamycin; COPD, chronic obstructive 
pulmonary disease. LETTERS
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Buruli Ulcer in 
Long-Term Traveler 
to Senegal
To the Editor: Buruli ulcer (BU) 
is caused by infection of subcutaneous 
fat with the environmental pathogen 
Mycobacterium ulcerans. BU has been 
reported or suspected in more than 30 
countries. It has never been reported 
in Senegal and Guinea-Bissau (1). We 
report a case of travel-associated BU 
in a French traveler to Senegal.
The patient was a 24-year-old 
Caucasian man who came to the Uni-
versity Hospital of Bordeaux, France, 
with a nonhealing lesion on the ante-
rior left leg that had been present for 
≈12 weeks. The patient had traveled in 
Senegal to the border of Guinea-Bis-
sau from September 2006 through Au-
gust 2007. His trip had begun in Dakar 
and proceeded south to the districts of 
Kaolack, Toubacouta, and Casamance. 
The patient stayed in Casamance dur-
ing the rainy season from June 2007 
through August 2007. He had been 
working on construction of wood dug-
outs, had been bare-legged regularly, 
and had been in contact with stagnant 
water.
He  ﬁ  rst noticed a lesion during 
June 2007, which had gradually in-
creased to a small, centrally crusted 
ulcer. By the end of August 2007 
(week 8 of the lesion), skin examina-
tion showed a 3 × 6-cm necrotizing 
ulcer with central crusting and an ery-
thematous border (Figure). The lesion 
was not warm or tender but generated 
a seropurulent discharge. Concurrent-
ly, palpable left inguinal lymph nodes 
were observed.
Bacteriologic swabs identiﬁ  ed 
Staphylococcus aureus and group A 
Streptoccocus pyogenes. Two punch-
biopsy specimens were taken from 
the border of the lesion. Histologic 
analysis showed nonspeciﬁ  c  acute 
and chronic dermal inﬂ  ammation 
with necrotizing granulomas that ex-
tended into the subcutaneous tissues, 
suggestive of infection with atypical 
Mycobacterium  spp. Bacteriologic 
examination did not identify acid-fast 
bacilli (negative direct smear result 
after Ziehl-Neelsen staining) or other 
speciﬁ  c microorganisms (negative di-
rect smear results after periodic acid–
Schiff, Giemsa, and Gram staining). 
Tissue specimens were placed into 
BACTEC 12B broth (Becton Dickin-
son, Franklin Lakes, NJ, USA) (incu-
bated at 35°C) and onto Löwenstein-
Jensen slants (incubated at 30°C). No 
growth was detected after 42 days. On 
the basis of clinical ﬁ  ndings, we sus-
pected a diagnosis of BU.
Taq-Man real-time quantita-
tive PCR that used primers for 2 M. 
ulcerans–speciﬁ   c genes (insertion 
sequence  2404 and ketoreductase 
B gene) (2,3) and negative controls 
showed positive results for DNA from 
both biopsy specimens. A normalized 
standard curve was constructed, which 
indicated a bacterial load of ≈6 × 103 
organisms/g of tissue.
Laboratory investigations indi-
cated a total leukocyte count of 16,400 
cells/μL (reference range 3,600–
10,000 cells/μL) and a C-reactive pro-
tein level of 0.59 mg/mL (reference 
value <0.01 mg/mL). Results of radio-
logic investigations were normal. The 
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Figure. Ulcer (3 × 6 cm) on anterior side of the left leg of the patient, showing an 
erythematous border.